AUTOIMMUNE OVERLAP SYNDROME: IMMUNOPATHOLOGICAL, CLINICAL AND CARDIOVASCULAR IMPLICATIONS OF COMORBID RHEUMATOID ARTHRITIS AND AUTOIMMUNE HYPOTHYROIDISM

Scientific advisor: **Abdushukurova Komila Rustamovna**
Samarkand State Medical University Senior Lecturer, Department of Internal Medicine No. 1
sukhrobkazimov@gmail.com
Egamshukurova Sevinch Abdumalik qizi
Student of Samarkand State Medical University
eegamshukurova@gmail.com
Tolibova Jasmina Jo'rabekovna
Student of Samarkand State Medical University
tolibovajasmin15@gmail.com
O'tkirova Zulkhumor Abdurashid qizi
Student of Samarkand State Medical University
Otkirovazulxumor04@gmail.com
Boboqulov Samoyiddin Ikhtiyor o'g'li
Samarkand State Medical University, 1st course Resident , cardiology department

Abstract:

Background: *Rheumatoid arthritis (RA) and autoimmune hypothyroidism (AH), predominantly Hashimoto's thyroiditis, are chronic immune-mediated disorders with overlapping genetic susceptibility and inflammatory mechanisms. Increasing epidemiological evidence indicates that their coexistence is more frequent than expected by chance.*

Objective: *To comprehensively analyze the epidemiology, shared immunopathogenesis, clinical expression, cardiovascular burden, and therapeutic implications of RA and autoimmune hypothyroidism comorbidity.*

Methods: *A structured review of cohort studies, case-control analyses, immunological investigations, and translational research was conducted to evaluate prevalence rates, cytokine profiles, autoantibody patterns, metabolic alterations, and cardiovascular outcomes in patients with RA and concomitant thyroid dysfunction.*

Results: *RA patients demonstrate a significantly increased prevalence of autoimmune hypothyroidism (10–30%) compared to the general population. Shared mechanisms include HLA-DRB1 susceptibility alleles, PTPN22 polymorphism, T-cell dysregulation, B-cell hyperactivity, and chronic overexpression of TNF-α and IL-6. Hypothyroidism contributes to amplified systemic inflammation, dyslipidemia, endothelial dysfunction, and increased cardiovascular morbidity. Thyroid dysfunction may also alter RA disease activity indices and therapeutic responsiveness.*

***Conclusion**: The coexistence of RA and autoimmune hypothyroidism represents a clinically significant autoimmune overlap syndrome. Integrated screening and multidisciplinary management are essential to reduce systemic complications and optimize long-term outcomes.*

Keywords: *Rheumatoid arthritis, Hashimoto's thyroiditis, autoimmune hypothyroidism, cytokines, DAS28, systemic inflammation, cardiovascular risk, immune dysregulation*

1. Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial inflammation, progressive joint destruction, and extra-articular manifestations. Beyond musculoskeletal involvement, RA is associated with accelerated atherosclerosis and increased cardiovascular mortality.

Autoimmune hypothyroidism, primarily Hashimoto's thyroiditis, results from immune-mediated destruction of thyroid follicular cells. It represents the most prevalent autoimmune endocrine disorder worldwide.

The frequent coexistence of RA and autoimmune hypothyroidism suggests a shared pathogenic framework. Patients with one autoimmune disease have a 2–4-fold increased risk of developing additional autoimmune conditions, reflecting systemic immune dysregulation.

This overlap has important implications:

Increased inflammatory burden

Amplified cardiovascular risk

Altered pharmacodynamics of immunomodulatory therapy

Diagnostic complexity due to overlapping clinical features

Understanding the mechanistic link between these diseases is essential for precision medicine approaches.

2. Epidemiology of Comorbidity

Multiple cohort studies demonstrate that hypothyroidism prevalence in RA patients ranges between 10% and 30%, significantly exceeding rates in the general population (4–10%).

Key epidemiological observations:

Female predominance in both conditions

Higher incidence in middle-aged populations

Increased anti-TPO antibody positivity in RA cohorts

Stronger association in seropositive RA (RF and anti-CCP positive patients)

Subclinical hypothyroidism appears particularly common in RA patients, often remaining undiagnosed without routine screening.

3. Shared Immunopathogenesis

3.1 Genetic Susceptibility

Both RA and autoimmune hypothyroidism share genetic polymorphisms affecting immune tolerance:

HLA-DRB1 “shared epitope” alleles

PTPN22 gene mutation (lymphoid tyrosine phosphatase regulation)

CTLA-4 gene polymorphisms

These genes contribute to defective central and peripheral immune tolerance, facilitating autoreactive lymphocyte survival.

3.2 T-cell Dysregulation

RA and Hashimoto’s thyroiditis both involve:

Th1 and Th17 cell activation

Reduced regulatory T-cell (Treg) function

Increased production of IL-17, IFN-γ, and TNF-α

Th17-mediated inflammation plays a pivotal role in synovial destruction in RA and thyroid follicular apoptosis in Hashimoto’s disease.

3.3 B-cell Hyperactivity and Autoantibody Production

B-cell activation leads to production of:

In RA:

Rheumatoid factor (RF)

Anti-cyclic citrullinated peptide (anti-CCP)

In Autoimmune Hypothyroidism:

Anti-thyroid peroxidase (anti-TPO)

Anti-thyroglobulin antibodies

The coexistence of multiple autoantibodies reflects systemic immune activation and epitope spreading.

3.4 Cytokine Network Overlap

Chronic elevation of pro-inflammatory cytokines is central to both diseases:

TNF-α

IL-6

IL-1β

IFN-γ

IL-6 is particularly important because:

It stimulates CRP production

Promotes B-cell differentiation

Contributes to thyroid tissue destruction

Drives RA synovitis

Biologic agents targeting IL-6 and TNF-α may theoretically influence thyroid autoimmunity progression, though data remain limited.

4. Clinical Interactions and Diagnostic Challenges

4.1 Symptom Overlap

Both RA and hypothyroidism present with:

Fatigue
Myalgia
Joint stiffness
Cognitive slowing

Hypothyroidism may falsely elevate RA Disease Activity Score (DAS28), leading to overtreatment if thyroid dysfunction is unrecognized.

4.2 Impact on Disease Activity

Studies indicate:

Higher DAS28 scores in RA patients with hypothyroidism
Increased CRP and ESR levels
More pronounced functional disability

Correction of hypothyroidism with levothyroxine may improve perceived RA activity and reduce inflammatory markers.

5. Metabolic and Cardiovascular Consequences

RA alone increases cardiovascular mortality by approximately 50% due to chronic inflammation and accelerated atherosclerosis.

When hypothyroidism coexists, additional mechanisms emerge:

Elevated LDL cholesterol
Increased triglycerides
Diastolic hypertension
Arterial stiffness
Endothelial dysfunction

Subclinical hypothyroidism further worsens lipid metabolism and promotes carotid intima-media thickening.

The combined inflammatory and metabolic burden significantly amplifies:

Coronary artery disease risk
Heart failure incidence
Thromboembolic complications

6. Impact on Pharmacotherapy

Hypothyroidism may:

Alter methotrexate metabolism
Influence hepatic drug clearance
Modify response to biologic DMARDs

Conversely, TNF inhibitors and IL-6 blockers may modulate thyroid autoimmunity by suppressing systemic inflammation.

However, evidence remains inconclusive and requires further longitudinal research.

7. Biomarkers and Screening Recommendations

Recommended evaluation in RA patients:

TSH
Free T4

Anti-TPO antibodies
Lipid profile
CRP and ESR
High-risk groups for screening:
Female patients
Seropositive RA
Persistent fatigue
Dyslipidemia
Cardiovascular risk factors

Routine thyroid screening every 1–2 years may be justified in chronic RA management.

8. Discussion

The RA–autoimmune hypothyroidism overlap represents a model of systemic autoimmunity driven by genetic susceptibility and chronic cytokine activation.

This comorbidity should not be considered incidental. Instead, it reflects shared immunological pathways with cumulative systemic consequences.

The additive inflammatory and metabolic burden significantly increases cardiovascular morbidity. Early identification and integrated management may reduce long-term complications.

Future research directions include:

Longitudinal cohort studies evaluating biologic therapy impact on thyroid autoimmunity
Investigation of Th17-targeted therapies
Precision medicine approaches using immune profiling

9. Conclusion

Comorbid rheumatoid arthritis and autoimmune hypothyroidism constitute a clinically significant autoimmune overlap syndrome characterized by shared immunopathogenesis, amplified systemic inflammation, and increased cardiovascular risk.

Routine thyroid function assessment in RA patients is strongly recommended. Integrated rheumatologic and endocrinologic care is essential to optimize therapeutic outcomes and reduce morbidity.

REFERENCES

1. Cappola AR, Desai AS, Medici M, et al. Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment. Circulation. 2019;139(25):2892-2909

2.Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.

3.Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical 4.and

diagnostic criteria. Autoimmun Rev. 2014;13(4–5):391–397.

5.Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174–180.

6.Boelaert K. The association between autoimmune thyroid disease and other autoimmune disorders. Nat Rev Endocrinol. 2009;5(6):309–316.

7.Lazúrová I, Benhatchi K. Autoimmune thyroid diseases and rheumatoid arthritis: relationship and mechanisms. Clin Rheumatol. 2013;32(6):857–863.

8.Shiroky JB, Cohen M, Ballachey ML, Neville C. Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann Rheum Dis. 1993;52(6):454–456.

9.Raterman HG, et al. Thyroid disease in patients with rheumatoid arthritis: increased prevalence and its relationship with disease activity. Arthritis Res Ther. 2008;10(5):R99.

10.Biondi B, Kahaly GJ. Thyroid Hormones and Cardiovascular Function and Diseases. J Am Coll Cardiol. 2018;71(16):1781–1796.

11.Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725–1735.

12.Rodondi N, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–1374.

13.Prummel MF, Wiersinga WM. Thyroid autoimmunity and its associations with other autoimmune diseases. Eur J Endocrinol. 2004;150(6):751–756.

14.Ajeganova S, et al. Increased risk of cardiovascular disease in rheumatoid arthritis: mechanisms and implications. Nat Rev Rheumatol. 2016;12(10):598–610.

15. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697.